Ligustrazine Attenuates Hyperhomocysteinemia-induced Alzheimer-like Pathologies in Rats

• 作者: Qing ZHANG Jing WANG Liang ZHU Shi-jie JIANG Juan LIU Lin-xiao WANG Xi-hu QIN
• 来源期刊: 当代医学科学（英文）
• 年，卷（期）: 2021,（3）
• 所属期刊栏目: ORIGINAL ARTICLES
• 页码范围: 548-554
• 页数: 7页
• 语种: 英文
• DOI: 10.1007/s11596-021-2379-1

摘要

Ligustrazine,an alkaloid extracted from the traditional Chinese herbal medicine Ligusticum Chuanxiong Hort,has been clinically applied to treat the cerebrovascular diseases.Hyperhomocysteinemia(Hhcy)is an independent risk factor for Alzheimer's disease(AD).Memory deficits can be caused by Hhcy via pathologies of AD-like tau and amyloid-β(Aβ)in the hippocampus.Here,we investigated whether homocysteine(Hcy)can induce AD-like pathologies and the effects of ligustrazine on these pathologies.The Hey rat model was constructed by 14-day Hcy injection via vena caudalis,and rats were treated with daily intragastric administration of ligustrazine at the same time.We found that the pathologies of tau and Aβ were induced by Hcy in the hippocampus,while the Hcy-induced tau hyperphosphorylation and Aβ accumulation could be markedly attenuated by simultaneous ligustrazine treatment.Our data demonstrate that ligustrazine may be used as a promising neuroprotective agent to treat the Hcy-induced AD-like pathologies.